Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENIT	о г	CLIAN	
STATEMENT	OF	CHAI	NGE

ES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MENDLEIN JOHN					2. Issuer Name and Ticker or Trading Symbol <u>aTYR PHARMA INC</u> [LIFE]								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(F		(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/01/2015								(give title See Re	10% Owner Other (specify below)		1			
(Street) SAN DII (City)		tate)	92121 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					2A. Deemed Execution Date,			3. Transacti Code (Ins	on Disp	4. Securities Acquired (A) Disposed Of (D) (Instr. 3,			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		. Nature f Indirect eneficial bwnership nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	Code (Instr					6. Date Exercisable Expiration Date (Month/Day/Year)		of Securities		es J Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Ind (I) (Ins	(D) rect	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)	(D)	Date Exercisable	Expirat Date	tion	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$10.24	10/01/2015			A		71,000		(1)	10/01/2	2025	Common Stock	71,000	\$0.00	71,000	D			
Employee Stock Option (right to buy)	\$10.24	10/01/2015			A		65,070		(2)	(2)		Common Stock	65,070	\$0.00	65,070	D			

Explanation of Responses:

- 1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 1, 2015, such that this option will be fully exercisable on October 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- 2. The shares subject to this option shall vest and become exercisable, if at all, in 48 equal monthly installments upon the achievement of certain performance goals, which must be achieved by October 1, 2017, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Executive Chairman of the Board and Chief Executive Officer

/s/ Nancy Krueger, as Power of 10/05/2015 **Attorney**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.